Tom Cahill, MD, PhD is the Founder and Managing Partner of Newpath Partners, a Boston based life science venture fund focused on building therapeutic companies around transformational scientific discoveries. Newpath is a founding investor in most of their life science companies and focuses on uniquely aligning interests between academic scientists, investors, and management teams. Dr. Cahill currently serves as a Director at the following companies: Chroma Medicine, Exo Therapeutics, Kisbee Therapeutics, Kojin Therapeutics, Magnet Biomedicine, Myeloid Therapeutics, Nvelop Therapeutics, Prime Medicine, Resonance Medicine, and YourBio Health. In addition, Dr. Cahill is involved with non-profit and non-partisan groups such as Scientists to Stop COVID-19 (STSC-19) and the Personal Genetics Education Project (pgEd). Dr. Cahill received both his M.D. and Ph.D. from Duke University.